• Loading stock data...
Est. 2004

Wednesday 03/6/2019

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More


  • 11:09 AM

    Edgewater Wireless Systems Inc. (YFI; TSX.V) (OTCQB: KPIFF), the developer of WiFi3™ ultra-wideband, multi-channel WiFi for high-density/high-interference wireless applications, today announced the company’s Artificial Intelligence Radar (A.I.R.) module leveraging Galgus Cognitive Hotspot Technology. Edgewater Wireless aera™ access point products will offer A.I.R. as a standard feature to deliver the world’s first intelligent, real-time device tracking within any network coverage zone. A.I.R. uses an in-real-time artificial intelligence engine to learn from and adapt to any network environment or coverage zone with

    Read more
  • Immune Therapeutics
    2:10 PM

    ORLANDO Fla., April 11, 2016, IMUN, /PRNewswire/ — Immune Therapeutics, Inc. (OTCQB: IMUN); a clinical-stage international biotechnology company providing immunotherapy solutions for the treatment of diseases, autoimmune diseases, and cancer, announced today it is providing shareholders with a status update of Immune Therapeutics, Inc.’s (IMUN) drug development program in China with long-term partner Hubei Qianjiang Pharmaceutical Co. Ltd (Qianjiang). The Economist Intelligence Unit (EIU) projects $166 billion in drug sales in China by 2017, providing a recognized market to  further growth.

    Read more
  • Immune Therapeutics
    4:52 PM

    ORLANDO, Fla., March 3, 2016, IMUN, /PRNewswire/ — Immune Therapeutics, Inc. (OTC:BB IMUN), a specialty pharmaceutical company involved in the manufacture, commercialization, distribution and marketing of novel, patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system, today announced the appointment of two new members to its Board of Directors: Clifford A. Selsky, Ph.D., MD, and Paul Akin. “Paul Akin and Dr. Selsky ‘s breadth of knowledge and experience will provide invaluable insight to

    Read more
  • 3:50 PM

    ORLANDO, FL, IMUN, / ACCESSWIRE/ Immune Therapeutics Inc. a specialty biopharmaceutical company (OTCQB: IMUN) today provided an update on the ongoing clinical trial of Lodonal in Nigeria. The trial is an open-label, placebo-controlled study that includes a 90-day treatment period followed by a 60-day extension. The primary objective of this clinical trial is to confirm that Lodonal has a beneficial effect on the immune system of patients in Nigeria with a compromised immune system (refer to Inclusion/Exclusion Criteria). This will

    Read more
  • 12:49 PM

    VANCOUVER, Wash., Oct. 22, 2015, OTCQB, CYDY, (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV) infection, today announced that the first patient in its Phase 3 clinical trial has been injected with PRO 140, the Company’s monoclonal antibody for the treatment of HIV. PRO 140 is the first self-injectable antibody in a Phase 3 protocol involving 300 HIV patients that will each be evaluated over a

    Read more
  • 2:27 PM

    Sep 25, 2015 OTC Disclosure & News Service – FLEMINGTON, N.J., Sept. 25, 2015, OTCQB, ARNI, (GLOBE NEWSWIRE) — Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and other life threatening diseases, today announced that a late-breaking abstract on AR-12 has been accepted for poster presentation at the upcoming 15th European AIDS Conference, hosted by the European AIDS Clinical Society (EACS) and being held October 21-24 in Barcelona, Spain. Logistical details

    Read more
Public Wire Banner